SandRidge Energy Inc. (NYSE: SD) reported second-quarter 2013 results before markets opened this morning. The independent oil and gas company posted adjusted diluted earnings per share (EPS) of $0.08 on revenues of $512.99 million. In the same period a year ago, the company reported EPS of $0.07 on revenues of $478.43 million. Second-quarter results also compare to the Thomson Reuters consensus estimates for a net loss of $0.03 per share and $424.16 million in revenues.
On a GAAP basis SandRidge posted a loss of $0.07 per share.
The company replaced its CEO in June and gave four of its nine board seats to hedge fund TPG-Axon, which had forced the removal of founder and former CEO Tom Ward following allegations of directing some of the SandRidge�� business to outside firms in which Ward had an interest. Ward is also a co-founder of Chesapeake Energy Corp. (NYSE: CHK).
SandRidge provided updated guidance that was a significant jump to its previous outlook. Total production of oil and gas rose from 32.7 million barrels of oil equivalent to 33.3 million barrels. Production costs per barrel were shaved by lower general and administrative expenses and a lower interest expense. The company also raised its full-year average oil differential from $8.50 to $9.50 a barrel, reflecting higher volume of natural gas liquids and a decrease in premiums for its Louisiana Light Sweet crude oil.
Best Small Cap Companies To Buy Right Now: (ARM)
ARM Holdings plc, together with its subsidiaries, engages in the design of microprocessors, physical IP, and related technology and software; and sale of development tools to enhance the performance of high-volume embedded applications. Its products include microprocessors cores, such as specific functions comprising video and graphics IP, fabric IP, embedded software, and configurable digital signal processing IP; physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components; software development tools that help software design engineers in the design and deployment of code, from applications running on open operating systems to low-level firmware. The company also offers support, maintenance, and training services, as well as design consulting services. ARM Holdings plc licenses and sells its technology and products to electronics companies, which in turn manufacture, market, and s ell microprocessors, application-specific integrated circuits, and application-specific standard processors to systems companies for incorporation into various end products, as well as licenses and sells development tools directly to systems companies and provides support services to licensees, systems companies, and other systems designers. It operates in Europe, the United States, and the Asia Pacific. The company was formerly known as Advanced RISC Machines Holdings Limited and changed its name to ARM Holdings plc in March 1998. ARM Holdings plc was founded in 1990 and is based in Cambridge, the United Kingdom.
Advisors' Opinion:- [By Namitha Jagadeesh]
ARM Holdings Plc (ARM) surged 12 percent after the designer of chips for Apple Inc.�� iPhone said April 23 that first-quarter revenue rose 29 percent to 170.3 million pounds. That beat the 160 million-pound average estimate of analysts surveyed by Bloomberg.
- [By Tom Stoukas]
ARM Holdings Plc (ARM), whose chip designs power Apple Inc.�� iPhone and iPad, plunged 5.2 percent to 995 pence. Exane BNP Paribas downgraded the shares to neutral from outperform, saying that Intel Corp.�� new platform may enable it to outperform ARM�� designs.
Top 10 Gas Utility Stocks To Buy Right Now: Polydex Pharmaceuticals Ltd (POLXF.PK)
Polydex Pharmaceuticals Limited, incorporated on June 14, 1979, is engaged in the research, development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the global veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. Dextran, a generic name applied to certain synthetic compounds formed by bacterial growth on sucrose, is a polymer or giant molecule. The products of the Company include Iron Dextran and Dextran Sulphate. The wholly owned subsidiaries of the Company include Dextran Products Limited (Dextran Products) and Chemdex Inc (Chemdex).
Iron Dextran
Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. The Company sells Iron Dextran to independent distributors and wholesalers in Europe, the Far East and Canada. Chemdex, Inc. has United States FDA approval for the manufacture and sale of Iron Dextran for veterinary use.
Dextran Sulphate
Dextran Sulphate is a specialty chemical derivative of Dextran used in research applications by the pharmaceutical industry and other centers of chemical research. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors and wholesalers in the United States and Europe as analytical chemical applications.
Advisors' Opinion:- [By The GeoTeam]
Polydex Pharmaceuticals (POLXF.PK) Limited, through its subsidiaries, engages in the development, manufacture, and marketing of biotechnology-based products for the human pharmaceutical market. It is also involved with manufacture of bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It primarily offers Dextran and Dextran derivative products.
Top 10 Gas Utility Stocks To Buy Right Now: Gen-Probe Incorporated(GPRO)
Gen-Probe Incorporated engages in the development, manufacture, and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood. Its women?s health product line includes APTIMA Combo 2 assay, APTIMA CT, APTIMA GC assays, and PACE family of assays to detect chlamydia and gonorrhea; APTIMA Trichomonas ASRs to detect trichomonas; APTIMA HPV assay to detect 14 sub-types of high-risk HPV associated with cervical cancer; and AccuProbe Group B Streptococcus (GBS) assay to detect GBS from culture. The company?s infectious diseases product line comprises ProFlu+ to detect influenza A, B, and Respiratory syncytial virus; ProFAST+ to detect and differentiate seasonal H1, seasonal H3, and H1N1pdm09; ProGastro Cd to detect toxigenic strains of clostridium difficile; AMPLIFIED MTD to detect mycobacterium tuberculosis; GAS Direct to detect gas directly from a throat swab; APTIMA HIV-1 and APTIMA HCV assays to detect RNA from HIV-1 and hepatitis C virus; and ASRs for quantitative HCV testing. Its blood screening products include Procleix HIV-1/HCV, Procleix Ultrio, Procleix Ultrio Plus, and Procleix WNV assays to detect HIV-1, HCV, HBV, and west nile virus in donated blood, plasma, organs, and tissues. The company?s transplant diagnostics products comprise LIFECODES HLA DNA typing kits; LIFECODES HLA antibody kits; LIFECODES PF4 assay to detect PF4 heparin-dependent antibodies; and LIFECODES PAK products for platelet antibody screening and detection. It also provides instrumentation and software for performing NAT assays; and genetic testing products, such as PROGENSA PCA3 and PCA3 ASRs to detect the PCA3 genes. The company serves reference laboratories, public health institutions, and hospitals through its direct sales force in United States, Canada, and Europe, as well as through distributors internationally. Gen-Probe Incorporated was founded in 1983 and is headquartered in S an Diego, California.
Advisors' Opinion:- [By Matt Egan]
While Nasdaq missed out on Alibaba, it did land a number of high-profile tech IPOs this year, including Weibo (WB), JD.com (JD) and GoPro (GPRO), which zoomed over 30% higher in its debut on Thursday. Nasdaq said 62% of all U.S. IPOs so far this year have occurred on its exchange.
- [By MONEYMORNING.COM]
Action-camera company GoPro Inc. (Nasdaq: GPRO) released more information about its upcoming IPO on Wednesday, saying the company plans to raise up to $427.2 million in the deal. That would give the company a valuation of approximately $3 billion.
Top 10 Gas Utility Stocks To Buy Right Now: OraSure Technologies Inc.(OSUR)
OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States and internationally. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The company offers OraQuick ADVANCE HIV-1/2, a point-of-care qualitative test for antibodies to the human immunodeficiency virus type 1 and type 2; OraQuick HCV, a point-of-care qualitative test for antibodies to the hepatitis C virus; OraSure QuickFlu Rapid Flu A&B Test, a point-of-care qualitative test for antibodies to influenza Types A and B, including H1N1 infections; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1 in an oral fluid sample in a laboratory setting; and Intercept, an oral fluid collection device for oral fluid drugs of abuse testing in a laboratory setting. In addition, it provides MICRO-PLATE DOA Assays that are used to detect the drugs in an oral fluid sample collected with intercept device; cryosurgical freezing systems for the removal of warts and other benign skin lesions; and cryosurgical systems for the removal of common and plantar warts. Further, OraSure Technologies sells immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test results obtained from the use of OraSure collection device; and Q.E.D., a point-of-care saliva alcohol test. The company sells its products through direct sales, strategic collaborations, and distributors to clinical laboratories, hospitals, clinics, community-based and other public health organizations, distributors, government agencies, physicians? offices, and commercial and industrial entities. It has collaboration agreement with Merck & Co. Inc. OraSure Technologies, Inc. was founded in 1979 and is based in Beth lehem, Pennsylvania.
Advisors' Opinion:- [By Sam Collins]
OraSure Technologies (OSUR) — This small-cap company develops, manufactures and markets oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies.
- [By Keith Speights]
Progress has also been made on the diagnostic front. The FDA approved OraSure Technologies' (NASDAQ: OSUR ) OraQuick home HIV test in July 2012. OraQuick allows an individual to use a mouth swab and find out the results within 40 minutes. The test hasn't exactly leaped off store shelves as of yet, though. OraSure reported only $1.5 million in gross sales for the OraQuick home test during the most recent quarter.
- [By Seth Jayson]
OraSure Technologies (Nasdaq: OSUR ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), OraSure Technologies beat slightly on revenues and met expectations on earnings per share.
Top 10 Gas Utility Stocks To Buy Right Now: Knightsbridge Tankers Limited(VLCCF)
Knightsbridge Tankers Limited, through its subsidiaries, engages in the seaborne transportation of crude oil and dry bulk cargoes worldwide. The company?s customers include oil companies, tanker companies, dry bulk companies, petroleum products traders, government agencies, and other entities. As of September 6, 2011, it owned and operated a fleet of four double-hull very large crude carriers, and four Capesize dry bulk carriers. The company was founded in 1996 and is based in Hamilton, Bermuda.
Advisors' Opinion:- [By Maxx Chatsko]
The horrendous flops
I wrote a blog post explaining why Knightsbridge Tankers (NASDAQ: VLCCF ) made the right move in slashing its dividend and why its prospects were looking up. The shipping company was extremely undervalued at the time, so why was I wrong? I made the mistake of thinking that a company trading below book value represented good value for shareholders. In reality, many shipping companies were -- and are -- trading below shareholders' equity because their fleets are enormously valuable assets. Unfortunately, that inflates book value enormously. It may not seem so harmful at first, but perpetually low charter rates have actually forced many shippers -- including Knightsbridge -- to sell tankers at less than market value to keep the lights on. Those practices can erase large chunks of book value overnight.
Top 10 Gas Utility Stocks To Buy Right Now: Durect Corporation(DRRX)
DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical products and therapies based on its proprietary drug formulations and delivery platform technologies. The company sells ALZET osmotic pumps for animal research use; LACTEL biodegradable polymers, which are used as raw materials in pharmaceutical and medical products; and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of Remoxy, an oral oxycodone gelatin capsule for the treatment of chronic pain under approval stage with the U.S. Food and Drug Administration; POSIDUR, a Phase III clinical stage sustained-release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II clinical stage transdermal bupivacaine patch intended to provide continuous delivery of bupivacaine for up to three days from a single application for pain; and TRANSDUR, a Phase II clinical stage transdermal sufentanil patch intended to provide continuous delivery of sufentanil for up to seven days from a single application for chronic pain. The company?s Phase II clinical stage products comprise ORADUR-based opioid for the treatment of pain; and ORADUR-ADHD for the treatment of attention deficit hyperactivity disorder. It also conducts various research programs covering diseases and medical conditions of the central nervous system, cardiovascular disease, and cancer. The company has strategic agreement with Hospira, Inc.; Alpharma Ireland Limited; Nycomed Danmark ApS; Pain Therapeutics, Inc.; Pfizer Inc; Endo Pharmaceuticals Inc.; and EpiCept Corporation. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 name that's starting to move within range of triggering a major breakout trade is Durect (DRRX), which develops pharmaceutical products based on its proprietary drug delivery technology platforms. This stock is off to a hot start in 2013, with shares up sharply by 41%.
If you take a look at the chart for Durect, you'll notice that this stock has been trending sideways for the last two months and change, with shares moving between $1 on the downside and $1.34 on the upside. Shares of DRRX have now started to flirt with that $1.34 major resistance level on Thursday, since the stock has hit an intraday high of $1.35 a share with strong upside volume flows. This could be signaling that shares of DRRX are ready to break out above the upper-end of its recent range and trend substantially higher.
Traders should now look for long-biased trades in DRRX if it manages to break out above some near-term overhead resistance levels at $1.34 to $1.35 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 679,480 shares. If that breakout triggers soon, then DRRX will set up to re-fill some of its previous gap down zone from May that started near $1.80 a share. If DRRX gets into that gap with volume, then this stock could easily trend north of $2 a share.
Traders can look to buy DRRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at its 50-day moving average of $1.16 a share or its 200-day moving average at $1.11 a share. One can also buy DRRX off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Gas Utility Stocks To Buy Right Now: SofTech Inc (SOFT)
SofTech, Inc., incorporated on June 11, 1969,is a provider of engineering software solutions with its ProductCenter PLM (product lifecycle management) technology and its computer-aided design product CADRA offering. On May 24, 2011, the Company sold its Advanced Manufacturing Technology (AMT) product line. In October 2013, SofTech, Inc announced that it has completed the sale of substantially all of the assets of its CADRA product line.
ProductCente
The Company's ProductCenter technology manages the engineering data and electronic files of discrete parts designed in third party design technologies offered primarily by Solidworks, Parametric Technology Corporation (PTC) and Autodesk. ProductCenter is an enterprise, collaborative PLM solution delivering a combination of document management, design integration, configuration control, change management, bill of materials management and integration capability with other enterprise systems. ProductCenter is designed to help companies optimize the product development process. ProductCenter provides for the secure management of product information and allows engineers and the entire design chain to manage, share, modify and track product data and documents throughout the product development lifecycle.
The Company�� ProductCenter supports engineering change management and bill of materials management for automating business processes. ProductCenter also enables integration with other business applications, such as enterprise resource planning (ERP), supply chain management (SCM) and customer relationship management (CRM) for continuous data exchange across the product lifecycle.
CADRA
The Company�� CADRA offering is a drafting and design software package for the professional mechanical engineer. The CADRA family of CAD/CAM products includes CADRA Design Drafting, a mechanical design documentation tool, CADRA NC, a 2 through 5 axis NC programming application, and CADRAWorks with SolidWorks p! roviding for an integrated drawing production system and three dimensional (3D)solid modeler. The CADRA family of products includes a collection of translators and software options.
The Company competes with Autodesk, Dassault, Siemens, and PTC
Advisors' Opinion:- [By Peter Graham]
Small cap stocks New China Global (OTCMKTS: NCGI), RealBiz Media Group Inc (OTCMKTS: RBIZ) and SofTech, Inc (OTCMKTS: SOFT) sank 21.11%, 14.81% and 10.89%, respectively, last Friday. Moreover, two of these three small caps have been the subject of paid promotions or investor relations activities, but this week is the start of a new trading week and anything can happen. So will these three small cap stocks keep sinking? Here is a closer look to help you decide on an investing or trading strategy:
- [By Peter Graham]
Small cap tech, mobile or cloud computing stocks SofTech, Inc (OTCMKTS: SOFT), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Izea Inc (OTCMKTS: IZEA) have been getting some extra attention lately in various investment newsletters or alerts. That�� because at least one of these stocks appears to be the subject of paid third party promotions while another is the focus of an apparent investor relations campaign. Keeping that in mind, are these three tech orientated stocks going to bring profits to investors and traders or bring out the luddite in them? Here is a closer look:
No comments:
Post a Comment